Publications
- Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups2021 | Faculty of Medicine in Hradec Králové
- Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy2020 | Faculty of Medicine in Hradec Králové
- The role of the immune system and the biomarker CD3+CD4+CD45RA-CD62L-in the pathophysiology of migraine2020 | Faculty of Medicine in Hradec Králové
- CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate2019 | Faculty of Medicine in Hradec Králové
- Monitoring of Lymphocyte Populations During Treatment with Interferon--1b to Predict Multiple Sclerosis Disability Progression2019 | Faculty of Medicine in Hradec Králové
- Lymphocyte populations and their change during five-year glatiramer acetate treatment2018 | Faculty of Medicine in Hradec Králové
- Lymphocytes in the treatment with interferon beta-1 b2017 | Faculty of Medicine in Hradec Králové
- Poruchy rovnováhy v dětském věku2023 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine, First Faculty of Medicine, Third Faculty of Medicine
- Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor2023 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis2023 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
Loading network view...